Labcorp receives fda approval for first companion diagnostic for use with pfizer's newly approved gene therapy to treat patients with hemophilia b

Assay expands company's leadership in precision medicine and cell and gene therapy burlington, n.c. , april 29, 2024 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, today announced the u.s. food and drug administration (fda) has approved its nabcyte™ anti-aavrh74var hb-fe assay, a companion diagnostic (cdx) to determine patient eligibility for treatment with beqvez™ (fidanacogene elaparvovec-dzkt), pfizer's recently fda-approved hemophilia b gene therapy.
LH Ratings Summary
LH Quant Ranking